Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

This study has been completed.
Information provided by:
Innovative Medical Identifier:
First received: June 30, 2006
Last updated: May 30, 2007
Last verified: May 2007
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Condition Intervention Phase
Drug: Bimatoprost 0.03%, Latanoprost
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Resource links provided by NLM:

Further study details as provided by Innovative Medical:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Documented low-responder to latanoprost therapy as delineated in the outline above.
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

  • · Known contraindication to bimatoprost or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
    • History of intraocular surgery within the last 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00347841

United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Principal Investigator: Robert Noecker, MD UPMC Eye Center
  More Information Identifier: NCT00347841     History of Changes
Other Study ID Numbers: 5178 
Study First Received: June 30, 2006
Last Updated: May 30, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Antihypertensive Agents processed this record on October 25, 2016